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LETTERS TO THE EDITOR
The need for contamination
control in studies on
lanthanum biodisposition
To the Editor: Whereas published data on the biodispo-
sition of lanthanum should be welcomed, those reported
by Lacour et al [1] give cause for concern. Concentra-
tions of lanthanum in plasma for control samples were
of the order of 400 ng/mL, and values were not signif-
icantly elevated in rats given lanthanum carbonate. In
independent studies we, and others, have obtained back-
ground levels 1000 to 10,000 times lower and routinely
differentiate plasma from control and lanthanum-treated
groups (see Fig. 1) [2]. In dialysis patients treated with
recommended doses of Fosrenol, steady state plasma
concentrations are <1 ng/mL [3] (see also Prescribing In-
formation), 400 times lower than in the placebo samples
in the Lacour et al [1] rat study. These results strongly sug-
gest contamination of analytical samples with lanthanum
from the animals’ environment.
It is well known that trace/ultratrace element determi-
nations are subject to potential analyte contamination at
all stages in the sampling/analytical process and, in our
experience with lanthanum, stringent precautions must
be taken to avoid contamination. Lanthanum’s low oral
bioavailability (0.0007% in rats) results in excretion of al-
most all the dose via feces into the animal’s environment,
contaminating skin and fur. This situation demands rigor-
ous contamination control measures when handling ani-
mals, during blood and urine collection, and at autopsy,
to avoid the transfer of exogenous lanthanum into ana-
lytical samples. The potential problems of contamination
in rodent studies, especially dietary studies, have recently
attracted strong interest from drug regulatory authorities,
leading to issuance of new draft guidelines on the conduct
of animal safety studies [4].
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Fig. 1. Plasma lanthanum concentrations in rats given a single oral dose
of lanthanum carbonate (1500 mg/kg) or vehicle (control) by gavage.
Values are mean ± SD; N = 6; LLoQ (lower limit of quantification)
= 0.05 ng/mL; values <LLoQ reported as 0.05 ng/mL. Manuscript in
preparation.
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Reply from the Author
We thank McLeod et al for having drawn attention to
an error in Figure 3A of our article published in a recent
issue of Kidney International [1]. The unit of plasma lan-
thanum has been erroneously indicated as ‘lg/mL’ when
in fact it should read ‘lg/L,’ as shown by the scan of a
randomly selected original laboratory sheet of the lan-
thanum determinations done in our study (Fig. 1). We
sent an erratum to the Editors earlier this month when
we became aware of this regrettable typographic error.
The erratum was published in the July 2005 issue.
We agree that every possible precaution should be
taken to avoid contamination of plasma and tissue sam-
ples by trace elements when given in large amounts to
experimental animals or man. It is true that in our study,
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rats received lanthanum carbonate in their food, not by
gavage like in the study by Behets et al [2]. Neverthe-
less, lanthanum tissue concentrations found in our study
were of same order of magnitude as those of the latter
study. Thus, the mean bone lanthanum content was near
300 ng/g (lg/kg) wet weight in the lanthanum carbonate-
overloaded uremic rats of our study and near 1500 lg/kg
wet weight in their lanthanum carbonate-overloaded ure-
mic rats. One has to consider that the animals of our study
ingested approximately 1800 mg/kg lanthanum carbonate
per day for a time period of only 4 weeks, whereas the
rats of their study were gavaged with a maximal daily
dose of 1000 mg/kg lanthanum carbonate for a time pe-
riod of 3 months. When correcting for this time factor,
it is fair to conclude that the measurements in the two
studies yielded comparable results. The lanthanum mea-
surement techniques were the same, namely, inductively
coupled plasma emission spectrometry.
McLeod et al point out that they and others routinely
differentiate plasma lanthanum concentrations measured
in lanthanum-treated groups from those determined
in control samples. They show Figure 1 demonstrating
plasma lanthanum concentrations before and after an
acute dose of lanthanum carbonate given to rats. How-
ever, when analyzing Figure 1 closely, it becomes ap-
parent that the plasma lanthanum concentration (near
350 lg/L) found 24 hours after the acute dose was prob-
ably not different from the lanthanum concentration in
control plasma samples. Note that the latter was below
the lower limit of quantification. In the rats of our study,
lanthanum carbonate was not given as an acute load, but
was ingested progressively during 24 hours. Therefore,
one would not expect a peak plasma concentration such
as the one shown in McLeod et al’s figure, but rather a
concentration near to the bottom line. This is exactly what
we found (200-500 lg/L).
In our opinion, the suspicion of sample contamination
that has been formulated based on a typographic error in
one of the figures of our article can be ruled out with a
reasonable degree of confidence.
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Lanthanum pharmacokinetics:
Are rat data misleading?
To the Editor: On the basis of higher urine lanthanum
recoveries in uremic rats, Lacour et al [1] conclude there
are “important differences in the pharmacokinetics of
lanthanum in chronic renal failure.” This seems not to
be the case in man. Indeed, in a series of Phase I stud-
ies carried out to support the development of Fosrenol,
plasma concentration versus time profiles, and pharma-
cokinetic parameters (Cmax, AUC0−t, t1/2 abs, and t1/2 elim)
were similar in healthy subjects and dialysis patients (see
Fig. 1, p. 2908) [2], excluding a significant role of the kid-
ney in the elimination of lanthanum and suggesting little
influence of end-stage renal disease (ESRD) on systemic
bioavailability. It is possible that higher absorption and,
hence, higher portal plasma and liver lanthanum concen-
trations may occur in renal failure without affecting sys-
temic plasma profiles, but no data are available on this at
the present time.
Sample contamination may have influenced the Lacour
et al [1] rat data, as plasma lanthanum concentrations
in the controls in this study were extremely high com-
pared to other studies [3]. Inevitably, there is contact be-
tween urine, feces, and spilled diet in standard rodent
metabolism cages and, hence, an opportunity exists for
the high concentrations of lanthanum present in diet and
feces to transfer to urine. The extent of contamination will
be proportional to the volume of urine washing over cage
surfaces and, as Lacour et al [1] highlight, urine volume
was markedly elevated in the uremic groups. Such con-
tamination is a common source of error in rat excretion
studies, particularly when poorly absorbed drugs, present
at very low concentrations (nmol/L) in body tissues and
fluids, are administered via the diet [4]. The potential for
contamination can be reduced by controlled gavage of
the drug directly into the stomach of the rats.
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